VKTX Stock Eyes Blockbuster Week Despite Share Offering — Retail Traders See A Stronger Hand In Buyout Talks
Retail traders floated Novo Nordisk, AbbVie and Eli Lilly as possible buyers, while others saw the offering as a sign Viking may go it alone.
Stocktwits
More News
Could Retatrutide Be Worth $10 Billion to Eli Lilly?
Key PointsEli Lilly has a deep pipeline in its core therapeutic area...
Nasdaq News: Markets
Can Novo's Rare Disease Pipeline Add a New Growth Pillar Beyond GLP-1?
NVO's rare disease pipeline gains momentum as Frehemgo and Sogroya receive positive CHMP opinions for EU approval, opening new growth opportunities beyond GLP-1.
Zacks
VKTX Stock Rises on Encouraging Weight-Loss Maintenance Results
Viking Therapeutics' shares jump 36% as VK2735 maintenance data show most weight loss is preserved with less-frequent dosing.
Zacks
Eli Lilly Could Be a '$2,000 Stock' in the Next 3 to 4 Years, Says Home Depot Co-Founder Ken Langone
Home Depot co-founder Ken Langone says Eli Lilly could hit $2,000 in 3 to 4 years, challenging Home Depot as his top portfolio holding.read more...
Benzinga
VKTX Stock On Track To Beat LLY, NVO This Month After Obesity Drug Data — Can Viking Win Over Wegovy And Zepbound Users?
Obesity specialist Lou Aronne said switching from a GLP-1 drug to a dual GLP-1/GIP drug could mean greater weight loss.
Stocktwits
Roche's Enicepatide Shows Weight Loss, HbA1c Gains in Phase II Study
RHHBY's enicepatide cut HbA1c and body weight in a phase II study, strengthening its obesity ambitions as it advances the drug into phase III.
Zacks
Ken Langone says Eli Lilly could be a $2,000 stock in 3 to 4 years
Ken Langone says Eli Lilly could be a $2,000 stock in 3 to 4 years...
CNBC Television-YouTube
Should Dividend Investors Buy Pfizer Stock for Its High Yield or Invest in Eli Lilly for Its Dividend Growth?
Key PointsEli Lilly's yield of 0.6% looks minimal, but that's only because of how incredibly well the stock has performed...
Nasdaq News: Markets
Novo's CagriSema Outshines Zepbound in Key Phase III Weight-Loss Study
NVO's CagriSema delivers greater weight loss than Eli Lilly's tirzepatide in T2D and 21% weight loss in obesity, strengthening its late-stage pipeline.